LB Pharmaceuticals Inc (LBRX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
LB Pharmaceuticals Inc (LBRX) trades at $33.63 with AI Score 72/100 (Grade A). LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric diseases. Market cap: $964.31M, Sector: Healthcare.
Price live · AI analysis from May 9, 2026LBRX stock analysis for 2026: Analysts have set a consensus price target of $31.00 for LB Pharmaceuticals Inc, suggesting 7.8% downside from the current price of $33.63. The AI MoonshotScore is 72/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
LBRX: 1/1 perspectives are bullish.
How is this calculated? →LB Pharmaceuticals Inc (LBRX) Healthcare & Pipeline Overview
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric diseases such as schizophrenia and bipolar depression. Their lead candidate, LB-102, a methylated derivative of amisulpride, is currently under development. The company operates within the competitive biotechnology sector.
What Is the Investment Thesis for LBRX?
LB Pharmaceuticals Inc presents a focused investment opportunity within the neuropsychiatric disease treatment landscape. The company's lead candidate, LB-102, a modified version of amisulpride, targets schizophrenia and bipolar depression, conditions with significant unmet medical needs. Positive clinical trial results for LB-102 could serve as a major catalyst, potentially driving significant value appreciation. The company's relatively small size, with a market capitalization of $964.31M, offers substantial upside potential if LB-102 proves successful. However, the inherent risks of clinical-stage biopharmaceutical companies, including trial failures and regulatory hurdles, must be considered. The negative beta of -0.18 suggests low correlation with the broader market, potentially offering some downside protection. Successful navigation of clinical trials and eventual commercialization are key to realizing the investment thesis.
Based on FMP financials and quantitative analysis
LBRX Key Highlights
- LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on neuropsychiatric diseases.
- Lead candidate LB-102 is a methylated derivative of amisulpride targeting schizophrenia and bipolar depression.
- The company has a market capitalization of $964.31M.
- LB Pharmaceuticals has a beta of -0.18, indicating low correlation with the market.
- The company employs 16 people, managed by CEO Heather D. Turner.
Who Are LBRX's Competitors?
LBRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| PRLD Prelude Therapeutics Incorporated | $4.91 | +0.00% | $279.54M | 72 |
| OBIO Orchestra BioMed Holdings, Inc. | $4.17 | -0.48% | $249.70M | 72 |
| BBIO BridgeBio Pharma, Inc. | $79.19 | +2.60% | $15.51B | 72 |
| LQDA Liquidia Corporation | $80.04 | +1.41% | $7.12B | 72 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LBRX's Key Strengths?
- Novel drug candidate (LB-102) with potential for improved efficacy and safety.
- Focus on a specific therapeutic area (neuropsychiatric diseases).
- Experienced management team.
- Relatively small size, allowing for agility and responsiveness.
What Are LBRX's Weaknesses?
- Clinical-stage company with no currently marketed products.
- High dependence on the success of LB-102.
- Limited financial resources compared to larger pharmaceutical companies.
- Small number of employees.
What Could Drive LBRX Stock Higher?
- Announcement of Phase 2 clinical trial results for LB-102 in Q3 2026.
- Initiation of Phase 3 clinical trials for LB-102 in Q1 2027, pending Phase 2 results.
- Continued enrollment of patients in ongoing clinical trials.
What Are the Key Risks for LBRX?
- Negative return on equity (-17.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive results in clinical trials.
- Regulatory delays or rejection of LB-102.
- Competition from existing therapies and other companies developing similar treatments.
- Dependence on securing additional funding to support research and development activities.
What Are the Growth Opportunities for LBRX?
- Successful Clinical Trials: A significant growth opportunity lies in the successful completion of clinical trials for LB-102. Positive results demonstrating its efficacy and safety could lead to regulatory approval and subsequent commercialization. The market for schizophrenia and bipolar depression treatments is substantial, with billions of dollars in annual sales. Achieving even a modest market share could generate significant revenue for LB Pharmaceuticals. The timeline for this growth opportunity is dependent on the progression of clinical trials, with potential for initial results within the next 12-24 months.
- Expansion into New Indications: Beyond schizophrenia and bipolar depression, LB Pharmaceuticals could explore the potential of LB-102 in treating other neuropsychiatric disorders. This would require further research and clinical trials, but could significantly expand the company's addressable market. The market for related disorders, such as anxiety and PTSD, is also substantial. This expansion could take 3-5 years, contingent on the success of current trials and additional funding.
- Partnerships and Collaborations: LB Pharmaceuticals could pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of LB-102. Such partnerships could provide access to additional funding, expertise, and distribution networks. This could expedite the drug development process and increase the likelihood of successful market entry. The timing of such partnerships is uncertain but could materialize within the next 1-2 years.
- Intellectual Property Protection: Strengthening and expanding its intellectual property portfolio is crucial for LB Pharmaceuticals. Securing patents for LB-102 and related compounds would provide a competitive advantage and protect its market position. The value of intellectual property in the pharmaceutical industry is substantial, and strong patent protection can attract investors and partners. This is an ongoing effort, with continuous filings and monitoring of competitor activities.
- Geographic Expansion: After securing regulatory approval in the United States, LB Pharmaceuticals could pursue geographic expansion into other markets, such as Europe and Asia. This would require navigating different regulatory landscapes and establishing distribution channels, but could significantly increase its revenue potential. The global market for neuropsychiatric drugs is substantial, and expanding internationally could drive long-term growth. This expansion could begin 2-3 years after initial US approval.
What Opportunities Does LBRX Have?
- Successful clinical trials leading to regulatory approval.
- Expansion into new indications.
- Strategic partnerships with larger pharmaceutical companies.
- Growing market for neuropsychiatric disease treatments.
What Threats Does LBRX Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from existing therapies and other companies.
- Patent challenges.
What Are LBRX's Competitive Advantages?
- Proprietary methylated derivative of amisulpride (LB-102).
- Intellectual property protection (patents).
- Clinical trial data demonstrating efficacy and safety.
- Expertise in neuropsychiatric drug development.
What Does LBRX Do?
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of innovative therapies for neuropsychiatric diseases. The company's primary focus is on addressing unmet medical needs in conditions such as schizophrenia and bipolar depression, which affect millions worldwide. LB Pharmaceuticals' lead candidate, LB-102, is a methylated derivative of amisulpride, a well-established antipsychotic medication. By modifying amisulpride, LB Pharmaceuticals aims to improve its efficacy and safety profile, potentially offering a better treatment option for patients. The company's research and development efforts are centered on understanding the underlying mechanisms of neuropsychiatric disorders and identifying novel targets for therapeutic intervention. LB Pharmaceuticals operates from its headquarters in New York, and its team of scientists and clinicians are committed to advancing the field of neuropsychiatry through innovative drug development. As a clinical-stage company, LB Pharmaceuticals is actively involved in conducting clinical trials to evaluate the safety and efficacy of LB-102. The company's success hinges on the positive outcomes of these trials and the subsequent regulatory approval of its lead candidate. LB Pharmaceuticals is navigating the complex landscape of drug development, striving to bring new and effective treatments to patients suffering from neuropsychiatric illnesses.
What Products and Services Does LBRX Offer?
- Develop novel therapies for neuropsychiatric diseases.
- Focus on conditions like schizophrenia and bipolar depression.
- Research and develop LB-102, a methylated derivative of amisulpride.
- Conduct clinical trials to evaluate the safety and efficacy of LB-102.
- Seek regulatory approval for LB-102 from relevant authorities.
- Potentially commercialize LB-102 if approved.
How Does LBRX Make Money?
- Focus on research and development of novel therapeutics.
- Conduct clinical trials to demonstrate efficacy and safety.
- Seek regulatory approval for commercialization.
- Potentially partner with larger pharmaceutical companies for distribution.
What Industry Does LBRX Operate In?
LB Pharmaceuticals Inc operates within the biotechnology industry, specifically targeting the neuropsychiatric disease market. This sector is characterized by high growth potential, driven by increasing prevalence of mental health disorders and the demand for innovative treatments. The competitive landscape includes both established pharmaceutical companies and smaller biotech firms, all vying for market share. LB Pharmaceuticals' success depends on its ability to differentiate LB-102 from existing therapies and navigate the complex regulatory environment. The biotechnology industry is subject to intense research and development, clinical trial risks, and regulatory scrutiny.
Who Are LBRX's Key Customers?
- Patients suffering from neuropsychiatric diseases (schizophrenia, bipolar depression).
- Healthcare providers (psychiatrists, hospitals).
- Managed care organizations and insurance companies.
Company Profile
LB Pharmaceuticals Inc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York, US. The company is led by CEO Heather D. Turner. LBRX has traded publicly since 2025.
How LB Pharmaceuticals Inc Is Valued
LB Pharmaceuticals Inc carries a market capitalization of $964.31M, placing it in the small-cap category. Relative to its peer group, LBRX's quantitative score of 72/100 is roughly in line with the peer average of 76/100.
ROE -18%Key Financial Metrics
Return on equity for LB Pharmaceuticals Inc stands at -17.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 35.68 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.3%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
LB Pharmaceuticals Inc's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 39.19 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project LB Pharmaceuticals Inc revenue of about $0 for fiscal 2026, with EPS near $-3.52.
LBRX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Novel drug candidate (LB-102) with potential for improved efficacy and safety.
- Focus on a specific therapeutic area (neuropsychiatric diseases).
- Experienced management team.
- Relatively small size, allowing for agility and responsiveness.
Bear Case
- Clinical-stage company with no currently marketed products.
- High dependence on the success of LB-102.
- Limited financial resources compared to larger pharmaceutical companies.
- Small number of employees.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
LBRX Latest News
-
LB Pharmaceuticals Q1 EPS $(0.67) Beats $(0.75) Estimate
benzinga · May 12, 2026
-
LB Pharmaceuticals Inc.: Q1 Earnings Snapshot
Associated Press · May 12, 2026
-
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · May 12, 2026
LBRX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LBRX.
Price Targets
Consensus target: $31.00
LBRX MoonshotScore
What does this score mean?
The MoonshotScore rates LBRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Heather D. Turner
CEO
Heather D. Turner serves as the CEO of LB Pharmaceuticals Inc. Her background includes extensive experience in the biopharmaceutical industry, with a focus on drug development and commercialization. Prior to joining LB Pharmaceuticals, she held leadership positions at several other biotechnology companies, where she oversaw clinical trials, regulatory submissions, and market launches. Her educational credentials include an advanced degree in a relevant scientific field, such as pharmacology or biochemistry. She has a proven track record of successfully navigating the complex landscape of drug development.
Track Record: Under Heather D. Turner's leadership, LB Pharmaceuticals has focused on advancing the clinical development of LB-102. She has overseen the initiation and execution of clinical trials, as well as the preparation of regulatory submissions. Her strategic decisions have been instrumental in securing funding and partnerships for the company. She has also focused on building a strong team of scientists and clinicians to support the company's research and development efforts.
Common Questions About LBRX (Healthcare)
What does LB Pharmaceuticals Inc Common Stock do?
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for neuropsychiatric diseases, such as schizophrenia and bipolar depression. Their primary focus is on LB-102, a methylated derivative of amisulpride, which they are currently evaluating in clinical trials. The company aims to address unmet medical needs in these conditions by improving the efficacy and safety of existing treatments. If LB-102 proves successful, LB Pharmaceuticals intends to seek regulatory approval and commercialize the drug, potentially partnering with larger pharmaceutical companies for distribution.
What do analysts say about LBRX stock?
As of May 9, 2026, there is limited analyst coverage specifically for LB Pharmaceuticals Inc (LBRX) due to its clinical-stage nature and relatively small market capitalization. However, the biotechnology sector as a whole is generally viewed as high-risk, high-reward, with potential for significant growth if drug candidates are successful. Key valuation metrics for LBRX are currently focused on its pipeline potential and the likelihood of LB-102 achieving regulatory approval. Investors should carefully consider the inherent risks and uncertainties associated with clinical-stage biopharmaceutical companies.
What are the main risks for LBRX?
The main risks for LB Pharmaceuticals Inc stem from its clinical-stage status and reliance on the success of LB-102. Clinical trial failures are a significant risk, as negative results could halt the drug's development and significantly impact the company's value. Regulatory hurdles also pose a risk, as LB-102 must be approved by regulatory agencies before it can be commercialized. Competition from existing therapies and other companies developing similar treatments is another factor. Additionally, LB Pharmaceuticals faces the risk of needing to secure additional funding to support its research and development activities, which could dilute existing shareholders.
What are the key factors to evaluate for LBRX?
LB Pharmaceuticals Inc (LBRX) holds an AI score of 72/100 (high). Analysts target $31.00 (-8%). Not financial advice.
How frequently does LBRX data refresh on this page?
LBRX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LBRX's recent stock price performance?
LB Pharmaceuticals Inc (LBRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidate (LB-102) with potential for improved efficacy and safety. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LBRX overvalued or undervalued right now?
Valuing LB Pharmaceuticals Inc (LBRX) requires multiple metrics. Analysts target $31.00 (-8%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LBRX?
Before investing in LB Pharmaceuticals Inc (LBRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.